Marrow Therapeutics discloses $53m Series A led by Scion and venBio
The earlier round was disclosed alongside a separate $120m Series B as Marrow unveiled its bone marrow-targeted medicines platform.
Marrow Therapeutics disclosed a $53 million Series A co-led by Scion Life Sciences and venBio on 17 November 2026. The company announced the earlier financing alongside a separate $120 million Series B. Together, the rounds fund development of genetic medicines for severe blood disorders.
Use of funds
Develop bone marrow-targeted genetic medicines
Advance MAR-101 toward clinical development